https://www.selleckchem.com/pr....oducts/jr-ab2-011.ht
S-707106 administration could not achieve the primary endpoint of this clinical trial (20% of responsive participants). AUC glucose decreased by -7.1% (SD, 14.8 [90% CI -14.8- -1.0], P=0.033) and -2.7% (14.5 [-10.2-3.4], P=0.18) at 12 and 24 weeks, respectively. S-707106 administration decreased AUC glucose significantly in participants with a high body mass index. Body fat percentage decreased by -2.5% (1.7 [-3.3- -1.8], P0.001), and body muscle percentage increased by 2.4% (1.6 [1.7-3.1], P0.001). S-707106 is an effecti
Like
Comment
Share
